Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI by Li, Xing'an et al.
RESEARCH ARTICLE Open Access
Proteomic characterization of an isolated fraction
of synthetic proteasome inhibitor (PSI)-induced
inclusions in PC12 cells might offer clues to
aggresomes as a cellular defensive response











Background: Cooperation of constituents of the ubiquitin proteasome system (UPS) with chaperone proteins in
degrading proteins mediate a wide range of cellular processes, such as synaptic function and neurotransmission,
gene transcription, protein trafficking, mitochondrial function and metabolism, antioxidant defence mechanisms,
and apoptotic signal transduction. It is supposed that constituents of the UPS and chaperone proteins are recruited
into aggresomes where aberrant and potentially cytotoxic proteins may be sequestered in an inactive form.
Results: To determinate the proteomic pattern of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12
cells after proteasome inhibition by PSI, we analyzed a fraction of PSI-induced inclusions. A proteomic feature of
the isolated fraction was characterized by identification of fifty six proteins including twenty previously reported
protein components of Lewy bodies, twenty eight newly identified proteins and eight unknown proteins. These
proteins, most of which were recognized as a profile of proteins within cellular processes mediated by the UPS, a
profile of constituents of the UPS and a profile of chaperone proteins, are classed into at least nine accepted
categories. In addition, prolyl-4-hydroxylase beta polypeptide, an endoplasmic reticulum member of the protein
disulfide isomerase family, was validated in the developmental process of PSI-induced inclusions in the cells.
Conclusions: It is speculated that proteomic characterization of an isolated fraction of PSI-induced inclusions in
PC12 cells might offer clues to appearance of aggresomes serving as a cellular defensive response against
proteasome inhibition.
Background
The ubiquitin proteasome system (UPS) involves a serial
enzymatic cascade of ubiquitin dependent protein degra-
dation through which to prevent aberrant and poten-
tially cytotoxic proteins from forming insoluble protein
aggregates [1]. Chaperones are a group of protein fold-
ing catalysts and protein transporters which also emerge
as active participants in protein degradation [2]. Coop-
eration of constituents of the UPS with chaperone pro-
teins mediate a wide range of cellular processes, such as
synaptic function and neurotransmission, gene tran-
scription, protein trafficking, mitochondrial function and
metabolism, antioxidant defence mechanisms, and apop-
totic signal transduction [3-5]. Dysfunction of the UPS
has been implicated in protein aggregation as a possible
cause for pathogenesis in a number of the age-related
neurodegenerative and chronic neurological disorders
[6]. Parkinson’s disease (PD) viewed as a representative
of these disorders is characterized by selective death of
dopaminergic neurons in the substantia nigra pars com-
pacta (SNpc) and by appearance of abundant proteinac-
eous inclusions known as Lewy bodies (LBs) [7].
One of current concepts in PD pathogenesis is to
understand the mechanism of LBs. Protein aggregation
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mental stages of LBs at cellular and molecular levels
[8,9]. Substantial progress has been made in understand-
ing of the mechanism for LBs, aggresome-related pro-
cess [10,11]. According to this hypothesis, dysfunction
of the UPS contributes to aggregation of aberrant and
potentially cytotoxic proteins into insoluble protein
aggregates. One protective way cells handle the species
of aggregated proteins is to compartmentalize them in
specialized inclusions called as aggresomes [12,13]. The
aggresome machinery is activated as the last resort if
constituents of the UPS and chaperone proteins fail to
reverse increasing level of the target proteins through
transient up-regulation of gene expression in the stress-
ful environment [14-16]. It is supposed that constituents
of the UPS and chaperone proteins are recruited into
aggresomes where aberrant and potentially cytotoxic
proteins may be sequestered in an inactive form [17,18].
However, proteins in aggresomes are to be revealed if
we elaborate on possible causation of formation of LBs:
largely owing to dysfunction of the UPS. Currently, the
proteomic analysis of proteinaceous inclusions, whether
for patients with PD or in vitro models of PD due to
disruption of mitochondria, offers a valuable tool to
study protein composition of aggresomes [19,20]. Tradi-
tionally, cellular fractionation has provided the means to
isolate a fraction of LBs from brain tissue of LB variant
of Alzheimer’s disease patients [21]. Therefore, an iso-
lated fraction of inclusions as the starting material is
suitable for proteomic analysis [22]. Although it
remained to be determined that LBs are bona fide in
vivo correlates of aggresomes [13], aggresomes and LBs
are similar in protein composition as well as morpholo-
gical structures [23]. At least, on the premise of the
inducible aggresomes in cultured cells [13] and the
emphasized purity and yield of organelles isolated
through cellular fractionation of samples [22], proteomic
characterization of inclusions can advance our knowl-
edge about nature of aggresomes [19].
The aim of this present work was to determinate the
proteomic pattern of proteasome inhibitor (PSI)-induced
inclusions formed in PC12 cells after proteasome inhibi-
tion by PSI. Our main results were that a fraction of
PSI-induced inclusions isolated from the cells was quali-
fied for proteomic analysis and that a proteomic feature
of the isolated fraction was characterized by the identifi-
cation of fifty six proteins.
Results
Evaluation of cell survival
Using the trypan blue staining, we examined the plasma
membrane integrity of the cells following exposure to
PSI for 48 h. Compared to the cells in dimethyl sulfox-
ide (DMSO) vehicle which were only shown as normal
living cells excluding trypan blue stain (Figure 1A:a), the
cells in PSI were shown as both abnormal living cells
and dead cells, capable and incapable of excluding the
dye, respectively (Figure 1A:b). Moreover, we quantita-
tively evaluated the decline of living cell density in the
cells in PSI. The percentage of living cells differed sig-
nificantly between the cells in the vehicle (100%) and
PSI (85%), P < 0.05 (Figure 1, A: c).
Evaluation of a procedure of cellular fractionation
Using the hematoxylin-eosin (H&E) histological staining,
we detected the eosinophilic PSI-induced inclusions in
the cells with exposure to PSI for 48 h. Compared to
the cells in the vehicle which were shown without no
morphological change in eosinophilic structure (Figure
1B:a), the cells in PSI were shown with distinct eosino-
philic inclusions (Figure 1B:b). Further, similar to indu-
cible inclusions from PC12 cells in PSI for 24 h or MES
cells in mitochondrial respiratory chain complex I inhi-
bitor, rotenone for 72 h [19,24], the PSI-induced inclu-
sions appeared with a focal, homogeneous shape and
displayed two types of morphology: nucleus-binding and
nucleus-free inclusions. It was assumed that some of the
PSI-induced inclusions were observed in the cytoplasm
of the remaining cells, whereas the others were extruded
into the extracellular space after destruction of the host
cells [25].
At the first stage of isolation, using the H&E histologi-
cal staining, we detected the eosinophilic PSI-induced
inclusions, collected in the fraction of initial pellets. By
homogenization of the cells with 0.5% NP-40 at 37°C
for 30 min and subsequent centrifugation at 80 × g for
15 min, an abundance of intact PSI-induced inclusions
(Figure 1B:c) was yielded. In practice, we also increased
the number of nucleus-free PSI-induced inclusions.
There was a significant difference in the percentage of
the nucleus-free to total PSI-induced inclusions between
the fraction of cells in PSI (51%; Figure 1B:d, Column 1)
and the fraction of initial pellets (69%; Figure 1B:d,-
Column 2), *P < 0.05.
At the second stage of isolation, using the H&E histo-
logical staining, we first detected the PSI-induced inclu-
sions, collected in the temporary and final fractions of
resulting pellets. By four time-dependent incubations of
the initial pellets with 200 U/ml DNase I at 37°C for dif-
ferent lengths of time during the 24 h period, the
increasing number of nucleus-free PSI-induced inclu-
sions were easily yielded at the cost of the gradual
decline of nucleus-binding PSI-induced inclusions, and
of which, when the one of the time-dependent incuba-
tions ran out for the entire 24 h, the increase of
nucleus-free PSI-induced inclusions instead of the
decline of nucleus-binding PSI-induced inclusions could
be most easily yielded. In detail, after the four time-
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Page 2 of 17Figure 1 Effect of proteasome inhibition by PSI on both cell survival and formation of PSI-induced inclusions in PC12 cells, and
assessment of a three-process fractionation procedure on isolation of PSI-induced inclusions from the cells. A, trypan blue staining of
cells: a, cell survival (open arrows) alone in cells exposed to DMSO vehicle for 48 h; b, cell survival and addition of cell death (closed arrows) in
cells exposed to 10 μM PSI for 48 h; c, percentages of the number of living cells. B, H&E histological staining of inclusions: a, cells in the vehicle;
b, nucleus-binding (open arrows) and nucleus-free (closed arrows) inclusions formed in cells in 10 μM PSI for 48 h; c, the two morphological
types of inclusions in the fraction of initial pellets; d, percentages of nucleus-free to total inclusions in the cells in PSI (Column 1) and in the
fraction of initial pellets (Column 2); e-h, the one (or two) morphological type (s) of inclusions in the first four temporary fractions of resulting
pellets; i, the one morphological type of inclusions in the final fraction of resulting pellets; j, percentages of nucleus-free to total inclusions in the
five fractions of resulting pellets (Column 3-7). C, alpha-SYN immunostaining for and H&E histological staining of inclusions: a and a’, cells in PSI;
b and b’, an isolated fraction of inclusions. D, immunoblotting for histone H1 in inclusions: a, bands of histone H1 in gel image; b, quantitative
level of histone H1 in densitometry. Scale bar, 10 μm.
Li et al. BMC Neuroscience 2010, 11:95
http://www.biomedcentral.com/1471-2202/11/95
Page 3 of 17dependent incubations for 1 h (Figure 1B:e), 6 h (Figure
1B:f), 12 h (Figure 1B:g) and 24 h (Figure 1B:h), the
inclusive regions of nucleus (close arrow heads) but not
the inclusive regions of inclusion (open arrows) within
the nucleus-binding PSI-inclusions were progressively
reduced. The percentage of the nucleus-free to total
PSI-induced inclusions in the temporary fraction of
resulting pellets which was collected after the one of the
four time-dependent incubations of the initial pellets for
1 h (79%; Figure 1B:j Column 3) differed significantly
from each of the percentages in the temporary fractions
of resulting pellets which were collected after the other
three of the four time-dependent incubations of the
initial pellets for 6 h (80%; Figure 1B:j Column 4), 12 h
(81%; Figure 1B:j Column 5) and 24 h (93%; Figure 1B:j
Column 6), *P < 0.05. Interestingly, by the incubation of
the initial pellets with 200 U/ml DNase I and 250 μg/ml
RNase A for 24 h, a large quantity of nucleus-free PSI-
induced inclusions instead of few nucleus-binding PSI-
induced inclusions was observed in the final fraction of
resulting pellets (Figure 1B:i). All percentages in the first
four temporary fractions of resulting pellets (Figure 1B:j,
Column 3-6) differed significantly from the percentage
in the final one (97%; Figure 1B:j Column 7), **P < 0.05.
At the second stage of isolation, we detected the
alpha synuclein (alpha-SYN) positive, eosinophilic
inclusions, collected in the isolated fraction of PSI-
induced inclusions, using the alpha-SYN immunostain-
ing and the H&E histological staining, and then
detected the relatively small amount of histone H1
present in the same fraction using the West blotting
for histone H1, one of the most abundant proteins in
the nucleus [26,27]. In general, subcellular particles,
such as cellular debris and technical artifacts, were cre-
ated after the homogenization at the first stage of iso-
lation, and in particular, nuclear proteins were
remained after the nucleus degradation at the second
stage of isolation. Thus, by centrifuging the final frac-
tion of resulting pellets in discontinuous Percoll-
mediated 12%-35% gradients at 35,000 × g for 30 min,
the intact PSI-induced inclusions could be easily
divided from these subcellular particles and collected
as preparation of the target fraction. On one hand,
whether the PSI-induced inclusions were formed in the
cells in PSI (Figure 1C:a and 1C:a′)o ri s o l a t e dt h r o u g h
cellular fractionation (Figure 1C:b and 1C:b′), they
were stained as alpha-SYN positive, eosinophilic struc-
tures. On the other hand, in comparison to the inten-
sive signal of blotted histone H1 in gel image and its
high level in the column diagram, both of which were
characteristic of the large amount of nuclear proteins
for the samples of the cells in the vehicle or in PSI,
the faint signal of blotted histone H1 in gel image and
its low level in column diagram were characteristic of
the trace of nuclear proteins for the sample of the iso-
lated fraction of PSI-induced inclusions (Figure 1D:a
and 1D:b). In the end, the pure intact PSI-induced
inclusions were found in the isolated fraction.
Two-dimensional (2-D) gel-based protein resolution
We detected the protein spot pattern of the isolated
fraction of PSI-induced inclusions using 2-D gel electro-
phoresis. Since aggresomes in cell culture models of PD
act as disposal grounds for insoluble protein aggregates
[4,11], we assessed proteome organization of the isolated
fraction of PSI-induced inclusions by systematic analysis
of protein complexes. Lysis buffer was added to the iso-
lated fraction of PSI-induced inclusions to split inclu-
sions, and an optimal formulation of rehydration
solution was used to dissolve proteins from the split-
products [28,29]. In conventional ultrasonic extraction,
the enhancement of extraction efficiency is attributed to
acoustic cavitation [20,30]. Thus, soluble proteins dis-
solved from the isolated fraction of PSI-induced inclu-
sions were successfully resolved in 2-D gel as many
individual protein spots. As with the two samples of
proteins extracted from the homogenates of the cells in
the vehicle and in PSI (Figure 2A:a and 2A:b), the sam-
ple of proteins extracted from the isolated fraction of
PSI-induced inclusions was resolved on the left and cen-
tral regions on 2-D gel (Figure 2A:c). That is the pro-
teins displayed here are acidic and neutral proteins, as
consistent with a previous observation that nervous sys-
tem proteins in rat are mainly composed of acidic and
neutral proteins [31]. In addition, most of the resolved
proteins were within the molecular weight range of pro-
tein markers or the pH scale of isoelectric points (pI) or
both of them. Undoubtedly, the proteomic profiling of
the soluble proteins extracted from the isolated fraction
was represented by the specific protein spot pattern in
2-D gel. Of the protein spots that were better focused in
at least three of the four gels, one hundred and fourteen
spots were reproducibly observed. Each spot was found
not to differ significantly in terms of appearance, disap-
pearance and shift. These protein spots of interest were
selected for identification via peptide mass fingerprinting
(PMF) (Figure 2A:d).
It is pointed out that values of both molecular mass
and pI supplied in a matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectro-
metry (MS) data file are usually theoretical. Some of the
spots identified as proteins were found to alter their
positions across 2-D gel in the present experimental
condition. In general, the observed difference most
probably reflects mechanisms for the augmentation of
ubiquitin fusion-protein expression in eukaryotes when
proteasomes are inhibited beyond a threshold level
[32-34].
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We detected experimental PMF spectra of the target
protein spots using MALDI-TOF MS, and then PMF
data for protein identification using two on-line proteo-
mic search engines. Preliminarily, a total of fifty six pro-
teins were identified after submission of their PMFs to
the ProPound search engine against the single NCBInr
database (shown in Additional file 1). Furthermore, forty
eight of the fifty six proteins were consistently identified
after submission of their PMFs to the Mowse score-
b a s e dM a s c o ts e a r c he n g i n ea g a i n s tt h em u l t i p l e
NCBInr, SwissProt, MSDB databases (shown in Addi-
tional file 1). For example, prolyl-4-hydroxylase beta
subunit (P4HB) identified via its PFM against the single
database is shown with a group of MS data, such as
32.4% sequence coverage, 0.000 expectation, 8 matched
peptides and theoretic sequences of the matched pep-
tides (Figure 2B:a and 2B:b). After consistent identifica-
tion via its PFM against the multiple databases, it was
shown with its three comparable score values, viz., a top
score value of 71 (> 61) compared to a runner up value
of 38 (< 61) for NCBInr branch, 71 (> 51) compared to
37 (< 51) for SwissProt branch, and 71 (> 56) compared
to 38 (< 56) for MSDB branch (Figure 2B:c to 2B:e).
The protein was ultimately determined.
Among the fifty six proteins, twenty were found to be
previously reported components of LBs. These compo-
nents of LBs identified in the isolated fraction of PSI-
induced inclusions are listed as follows: two key proteins
in the synthesis of neural transmitter dopamine (DA),
i.e. tyrosine hydroxylase (TH) and 14-3-3epsilon (No.1-
2) [35,36]; two microtubulins, i.e. tubulin alpha1 and
tubulin beta5 (tubb5) (No.8-9) [37]; two mitochondria
matrix proteins, i.e. ATP synthase beta subunit
(F1-ATPase beta) and ubiquinol-cytochrome c reductase
core protein 1 (Uqcrc1) (No.20-21) [38,39]; Cu, Zn
superoxide dismutase (C, Z-SOD; No.22) [40,41]; six
proteasomal subunits, i.e. proteasome subunit beta 5,
Figure 2 Coomassie blue staining of proteins resolved in 2-D gel and identification of P4HB via PMF.A ,r e p r e s e n t a t i v ep a t t e r n so f
protein spots: a, cells in vehicle; b, cells in PSI; c or d, the isolated fraction of PSI-induced inclusions before and after protein gel spot picking
from 2-D gel. B, identification of P4HB via PMF: a, an expanded full scan of PMF; b, the number of theoretically matched peptides and their
sequences after preliminary identification via PMF against the single NCBInr database; c-e, comparable values of Mowse score after consistent
identification via PMF against the multiple NCBInr, SwissProt, MSDB databases. Mowse score is -10×Log (P), where P is the probability that the
observed match is a random event. Significance levels in the multiple databases are 61 in NCBInr branch, 51 in SwissProt branch and 56 in
MSDB branch, respectively (p < 0.05). Close arrows indicate locations of the protein spots of interest in 2-D gel for identification, and theoretical
sequences of the matched peptides for P4HB after identification.
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some 26 S subunit ATPase 5, proteasome 26 S subunit
ATPase 6, proteasome 26 S subunit non-ATPase 11 and
proteasome 26 S subunit non-ATPase 13 (No.26-31)
[23,42]; and seven chaperone proteins, i.e. 27-kD heat
shock protein 1 (HSP27; No.32) [43], heat shock protein
32 (HSP32; No.33) [44], 70-kD heat shock protein 1A/
1B (HSP70; No.35) [23], 71-kD heat shock cognate pro-
tein (HSC70; No.36) [11], 14-3-3zeta (No. 43) [45,46],
T-complex polypeptide 1 beta subunit (TCP-1beta;
No.46) [47] and Valosin-containing protein (No.48) [48].
Comparatively, the twenty eight proteins were newly
identified and, if selected for further study, may provide
novel clues to our understanding of the potential pro-
teomic candidates of aggresomes in response to protea-
some inhibition by PSI. For the other eight proteins
w h i c hw e r ei n c o m p l e t e l yd e t e r m i n e db yt h eP r o f o u n d
search engine using the single NCBInr database alone
(shown in Additional file 2), maybe it’sp r e f e r a b l ef o r
them to be identified in the future since update on con-
struction of a protein reference database has been con-
sidered as a discovery resource for proteomics [19-21].
These proteins, most of which were recognized as a pro-
file of proteins within cellular processes mediated by the
UPS, a profile of constituents of the UPS and a profile
of chaperone proteins, are classed into at least nine
accepted categories [4,19,20]. Functional classification of
the fifty six proteins and their percentages are shown in
Figure 3. Given that in eukaryotes, aggresomes sequester
aberrant and potentially cytotoxic proteins from the a
wide range of cellular processes mediated through the
UPS and also serve as sites for the recruitment and con-
centration of constituents of the UPS and chaperone
proteins [11], to date the protein dataset are at the level
of proteomics valuable for characterization of aggre-
somes, induced in PC12 cells by PSI and also in vitro by
many other proteasome inhibitors such as lactacystin or
MG132 [4,14]. Moreover, the profile of chaperone pro-
teins, accounting for the predominant portion of the
protein dataset and classed into the category of protein
folding and transport, have been found in available lit-
eratures to share some similarity between protein
families and specialize in various cellular localization
resources (summarized in Additional file 3). They are at
Figure 3 Functional categories of proteins identified in PSI-induced inclusions. This pie chart shows that all the identified proteins are
classified into at least nine accepted categories as follows: 3.6% for synaptic function and neurotransmission (I); 8.8% for gene transcription (II);
3.6% for protein trafficking (III); 21.4% for mitochondrial function and metabolism (IV); 1.8% for antioxidant defense mechanisms (V); 5.4% for
apoptotic signal transduction (VI); 10.7% for ubiquitin dependent protein degradation (VII); 30.4% for protein folding and transport (VIII); and
14.3% for unknown function (IX). When a protein could be divided into more than one class of functions, it was indicated as the best known
class.
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information on relationship between chaperone proteins,
known as aggresome related proteins, and aggresomes,
known as intermediate compartments [11].
Validation
Proteins identified via PMF need validation to show
their biological presence. A candidate selected for vali-
dation was determined by three criteria as follows: it
was significantly focused as an individual spot in 2-D
gel and detected as with a desirable group of MS identi-
fication data; it has not been reported in published lit-
erature on LBs; it matches to commercial specific
antibody. Thus, we sought to determine whether P4HB,
a member of the protein disulfide isomerase (PDI)
family in endoplasmic reticulum (ER) lumen, was
present in PSI-induced inclusions in PC12 cells with
proteasome inhibition, and if so, whether it redistributed
from its cellular location resource during the induction
of inclusions. We validated P4HB in the developmental
process of PSI-induced inclusions in PC12 cells in PSI
using the P4HB immunostaining and the H&E histologi-
cal staining. Compared to the uniform immunostaining
throughout cytoplasm of the cells in the vehicle (Figure
4A), P4HB tended to converge to juxtanuclear regions
in the cells in PSI (Figure 4B to 4E). Specifically, after
proteasome inhibition by PSI for 12 h, P4HB was pre-
sent with immunostaining of asymmetric structures
throughout cytoplasm and around nuclei (Figure 4B);
after the proteasome inhibition for 24 h or 36 h, P4HB
was present with immunostaining of granular and ellip-
tical perinuclear structures (Figure 4C and 4D); after the
Figure 4 P4HB immunostaining for and H&E histological staining of PSI-induced inclusions developed in PC12 cells after proteasome
inhibition by PSI. A and A’, cells in the vehicle; B-E and B’-E’, cells in PSI for 12, 24, 36 and 48 h; F and F’, a fraction of inclusions isolated from
the cells in PSI for 48 h. Development of inclusions in the cells at the end of indicated points of PSI exposure is indicated as closed arrows, and
nuclei and juxta-inclusion nuclei indicated as closed arrow heads. Scale bar, 10 μm.
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immunostaining of spherical structures (Figure 4E),
which was also shown in the isolated fraction of PSI-
induced inclusions (Figure 4F). Further, compared to
hematoxylin staining of ovoid nuclei of the cells in the
vehicle (Figure 4A′), P4HB-captured structures stained
readily with eosin were present in the cells in PSI for
the different lengths of time (Figure 4B′ to 4E′)a n di n
the fraction of PSI-induced inclusions isolated from the
cells in PSI for 48 h (Figure 4F′).
Discussion
In this study, proteasome inhibition by PSI induced cell
death and formation of inclusions in PC12 cells. An end
point cell death estimated using trypan blue exclusion
assay confirmed the effect of proteasome inhibition by
PSI on survival of the cells. Cytoplasmic eosinophilic
PSI-induced inclusions in the cells were immunostained
to visualize alpha-SYN positive structures. Experimental
observations have been providing evidence that applica-
tion of proteasome inhibitors such as lactacystin and
(or) PSI to PC12 cells is closely associated with both cell
death and formation of inclusions [49-52]. Nevertheless,
low doses of PSI which produces the highest number of
inclusions in PC12 are not enough to induce massive
cell death in the cells, whereas increasing its doses lead
to mass damage of the cells which does not allow the
visualization of inclusions [24,52], as shown similarly in
PC12 cells with exposure to methamphetamine [9].
Thus, the administration of PSI to PC12 cells we
selected could induce the abundance of cytoplasmic
inclusions as well as a massive amount of cell death.
Besides, morphological maturation of the PSI-induced
inclusions could allow us to appreciate how their isola-
tion was achieved.
In the study, we developed a three-process fractiona-
tion procedure to isolate a fraction of PSI-induced inclu-
sions from the cell culture model of PD, and thereafter
characterized a proteomic feature of the isolated frac-
tion. Traditional fractionation for isolating any popula-
tion of organelles from cell cultures consists of two
major stages: homogenization of cell cultures to release
various populations of intact organelles, and fractiona-
tion of homogenate to isolate the population of targeted
organelles [22]. At the first stage of isolating PSI-
induced inclusions, a first process of fractionation
procedure was used to separate the abundance of
nucleus-binding and the nucleus-free PSI-induced inclu-
sions into the fraction of initial pellets. At the second
stage of isolation, a second process of fractionation
procedure was used to increase the nucleus-free PSI-
induced inclusions at the cost of declining the nucleus-
binding PSI-induced inclusions, after which the whole
PSI-induced inclusions were enriched into the fraction
of resulting pellets; in the next isolation, a third process
of fractionation procedure was used to purify PSI-
induced inclusions into the preparation of target frac-
tion. In the case of the target fraction that should be
prepared as starting material sufficient for proteomic
analysis, the 2-D gel-based protein resolution and the
PMF-based protein identification were used to define a
proteomic feature of the isolated fraction of PSI-induced
inclusions. Of a total of fifty six proteins identified,
twenty proteins such as TH were found to be previously
reported protein components of LBs, twenty eight pro-
teins such as eukaryotic elongation factor 2 (eEF-2)
were newly identified, and the other eight proteins were
in lower confidence for information about protein desig-
nation. These proteins, most of which were recognized
as a profile of proteins within cellular processes
mediated by the UPS, such as tubulin alpha 1, a profile
of constituents of the UPS, such as PSMC2, and a pro-
file of chaperone proteins, such as HSP27, are classed
into at least nine accepted categories. In addition, P4HB,
an ER member of the PDI family, was biologically vali-
dated in the developmental process of PSI-induced
inclusions in PC12 cells after proteasome inhibition by
PSI.
In nerve endings and particularly brain neurons, it is
likely that proteins are easily damaged owing to limita-
tion of intrinsic ability for repair and (or) regeneration,
level of relatively high oxygen and elevated metabolic
rate, and enzymatic- and auto-oxidation of neurotrans-
mitters such as DA. Protein degradation via the UPS
exerts an effect on the removal of damaged proteins
that are extensively linked to cellular processes, such as
synaptic function and neurotransmission (I), gene tran-
scription (II), protein trafficking (III), mitochondrial
function and metabolism (IV), antioxidant defense
mechanisms (V), apoptotic signal transduction (VI) [4].
Cooperation of constituents of the UPS (VII) with cha-
perone proteins (VIII) in protein degradation plays the
central role in these processes [53,54].
I. TH identified in the study is regulated at two levels: a
long-term regulation involves changes in enzyme synthesis
for several days, while a short-term regulation of enzyme
activity is arrested by direct phosphorylation of the protein
within several minutes [55]. Alpha-SYN diminishes TH
phosphorylation and activity in stably transfected dopami-
nergic cells [56]. Given that alpha-SYN aggregation is
induced by proteasome inhibitors [24] and that TH is
degraded through the UPS [57,58], it is not coincidence
that TH colocalizes with alpha-SYN in LBs [35].
II. eEF-2 identified in the study is one of the gene
transcription factors whose cellular level in protein turn-
over process is dependent on the UPS [59]. Proteasome
inhibition by proteasome inhibitors in cells activates
up-regulation of specific members of transcription factor
Li et al. BMC Neuroscience 2010, 11:95
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scription factors may be trapped by cytoplasmic protein
aggregates in response to proteasome inhibition [61,62].
In addition, eEF-2 is phosphorylated by specific eEF-2
kinase causing its complete inactivation [63], and rele-
vance of transient eEF-2 kinase to the UPS may define
cellular levels of eEF-2 between dephosphorylation and
phosphorylation [64]. Potentially phosphorylated eEF-2
might acquire aggregation competence in PC12 cells
after proteasome inhibition by PSI.
III. Tubulin alpha1 and tubb5 identified in the study
not only colocalize with alpha-SYN in LBs or other
alpha-SYN positive pathological structures, but also
initiate alpha-SYN fibril formation under pathological
conditions in vitro [37]. The binding between parkin
and tubulin led to increased ubiquitination and accel-
erated degradation of alpha- and beta-tubulins in
vitro [65].
IV. The UPS can influence mitochondria under patho-
logic conditions [66]. Proteasome inhibition by protea-
some inhibitors not only increases the generation of
reactive oxygen species (ROS) in mitochondria [67,68],
but also activates the compartmentalization of mito-
chondrial proteins in aggresomes [69]. The two mito-
chondrial proteins identified in the study and found as
components of LBs, F1-ATPase beta and Uqcrc1, might
be damaged by mitochondrial ROS.
V. Antioxidant enzyme C, Z-SOD identified in the
study is the most notable component of antioxidant pro-
tective defense system in response to oxidative stress by
both SOD mechanism and hydrogen peroxide system
mediated-protein modification [70-72]. Proteasome inhi-
bition by proteasome inhibitors has been shown to gen-
erate oxidative stress in vitro and potentiate
compensatory up-regulation of antioxidants as a protec-
tive mechanism against oxidative stress [14,73,74]. The
oxidative modification of C, Z-SOD is associated with
PD [75].
VI. Apoptosis is the major mechanism of neuronal
d e a t hi nP D .A p o p t o t i cr e s p o n s ei sq u a n t i f i e db ya l l
members of the annexin family, especially annexin V
[14,76]. Three members of the annexin family were
identified in the study. Proteasome inhibition by protea-
some inhibitor MG-132 in a dopaminergic neuronal cell
model (N27 cells) rapidly depolarized mitochondria
independent of ROS generation to activate the apoptotic
cascade [77]. Aggresomes may be viewed as the wrong
cellular compartments where apoptotic cascade proteins
are sequestered after detrimental effects of proteasome
inhibition by proteasome inhibitors on mitochondrial
homeostasis [78].
VII. Proteasomal subunits are in progress of the tightly
coordinated expression and integrated assembly under
physiological conditions [79,80]. However, under
proteolytic stress conditions elicited by proteasome inhi-
bitors, proteasomal subunits display the alterable profile
of expression and composition [14,81]. For example,
treatment of cells with proteasome inhibitors activates a
transient up-regulation of mRNAs of all proteasomal
subunits [82]. The alteration might represent a regula-
tory feedback mechanism attempting to reverse protea-
some inhibition [80,83], but if the compensatory
regulation fails to establish affection, proteasomal subu-
nits are recruited to aggresomes to ubiquitinate
and degrade protein (Figure 5) [11,42]. One beta subunit
of 20 S proteasome core particle and five ATPase-
dependent and ATPase-independent subunits of 19 S
proteasome regulatory particle were identified in the
study, but it is not known whether proteasomal subunits
rich in LBs exist as individual subunits or as part of the
intact complex [23,84,85].
VIII. Cells usually express diverse family members of
chaperones and different versions of a family member of
chaperones to block protein aggregation [2,86]. The cha-
perone proteins identified in the study own their specia-
lized protein similarities. The intra- and inter-specific
species of chaperones are listed by chaperone proteins
rich in LBs, such as members of the HSP70 family (in
particular, HSP70 and HSC70) and members of the
small HSP family (in particular, HSP27 and HSP32)
[11,23,43,44]. In substance, proteasome inhibition by
proteasome inhibitors increased initial and concerted
expression of major types of chaperone proteins in cyto-
plasm, ER and mitochondria [61,87,88]. The compensa-
tory induction of chaperone proteins can be beneficial
since aggresomes are supposed to recruit both constitu-
ents of the UPS and chaperone proteins to facilitate pro-
tein clearance within the structures [11].
A function for chaperone proteins in targeting aber-
rant and potentially cytotoxic proteins for degradation
via the UPS has been established in various ways [89].
In substance, act of the UPS might depend on the cel-
lular compartment-localized chaperone proteins to
guide it along proper pathways [89,90]. What this
means is that chaperon proteins in cytoplasm (in parti-
cular, TCP-1beta) are required for the ubiquitin pro-
teasome pathway (UPP) [91], chaperone proteins in ER
(in particular, 150-kD oxygen regulated protein)
required for the ER associated degradation pathway
(ERAD) [92], and chaperone proteins in mitochondria
(in particular, HSP60) required for the mitochondria-
associated degradation pathway (MAD) [87]. Diversity
of chaperones among cellular localization resources is
listed by spatially restricted subset of chaperone pro-
teins, such as cytoplasmic HSP27, ER luminal 78-kD
glucose-regulated protein (GRP78) and mitochondrial
HSP60 [69,93-95]. Relevance of chaperone proteins in
cytoplasm, ER and mitochondria to cytoplasmic
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Page 9 of 17Figure 5 Potential mechanisms by which constituents of the UPS and chaperone proteins may affect development of PSI-induced
inclusions in PC12 cells after proteasome inhibition by PSI. A, relevance of chaperone proteins in cytoplasm, ER and mitochondria resources
to cytoplasmic constituents of the UPS establishes multiple routes of the UPS to remove aberrant and potentially cytotoxic proteins [2,87]. The
interaction between constituents of the UPS and cytoplasmic chaperon proteins might present one route to protein degradation in cytoplasm,
UPP by which its target proteins serving as protein substrates of enzyme in the cytoplasm are directed by chaperone proteins to proteasomes
[2]. The coordination between constituents of the UPS and ER chaperone proteins might present another route to protein degradation in ER,
ERAD by which its target proteins serving as protein substrates of enzyme in lumen of the ER are bound to chaperone proteins, retro-
translocated through a multi-protein translocon complex across ER membrane, get ubiquitinated by ubiquitin ligases, and are subsequently
targeted for degradation by proteasomes [87]. New data support the notion that a route of the UPS similar to that observed in ERAD occurs in
mitochondria and therefore the name of MAD has been proposed [87]. B, constituents of the UPS in cytoplasm and chaperone proteins in
cytoplasm, ER and mitochondria resources, together with the protein substrates of the UPS, could be recruited to PSI-induced inclusions formed
in PC12 cells after proteasome inhibition by PSI.
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the UPS to remove aberrant and potentially cytotoxic
proteins [2,87], but in response to proteasome inhibi-
tion, constituents of the UPS in cytoplasm and chaper-
one proteins in cytoplasm, ER and mitochondria
resources, together with the protein substrates of
the UPS, are induced and recruited to aggresomes
(Figure 5) [11,87,90].
P4HB, also known as PDI [96], is a highly unusual
multifunctional polypeptide [97]. As with calcium-
binding proteins and GRPs which are two members of
the PDI family [92,98], P4HB acts through ERAD to
eliminate proteins unable to adopt native structure after
translocation into the ER [99]. On the basis of biological
information retrieved from the studies with two model
animals, Pongo abelii (accession No., gi|62287145|sp|
Q5R5B6.1) and Macaca fuscata fuscata (accession No.,
gi|110815912|sp|Q2HWU2.1),P 4 H Bh a sb e e nd e f i n e d
as follows: it acts as a structural subunit of various
enzymes, such as proly-4-hydroxylase; it catalyzes the
formation, breakage and rearrangement of disulfide
bonds; it serves as a natural protector against protein
aggregation at high concentration and for protein self-
assembly and aggregation at low concentration. Given
that up-regulation of the PDI family in dopaminergic
neurons might contribute to formation of LBs [100],
and that the formation of LBs may act to delay the
initiation of neuronal death and slow progression in
sporadic PD, the members of the PDI family identified
in the study might expand the defensive role for chaper-
one proteins in the development of PSI-induced
inclusions.
Aggresomes are often enriched with aggresome-related
proteins such as chaperone proteins [11]. Next, our task is
to establish an immunoblot method for semi-quantitative
or quantitative screening of the ten chaperone proteins
which were identified in the study but have not been
reported in available literatures on LBs. Also, further stu-
dies will be required to demonstrate whether or not these
proteomic candidates are recruited into aggresomes in
response to proteasome inhibition by many other protea-
some inhibitors (in particular, lactacystin or MG132). The
importance of validation experiments in proteomic analy-
sis and the collection of comparable data from further stu-
dies will motivate us to reveal aggresomes in protein
content.
Conclusions
Taken together, the fifty six proteins identified by pro-
teomic analysis are associated with the isolated fraction
of PSI-induced inclusions in PC12 cells after proteasome
inhibition by PSI, and at this stage of the study, it is
speculated that proteomic characterization of an isolated
fraction of PSI-induced inclusions in PC12 cells might
offer clues to appearance of aggresomes serving as a cel-
lular defensive response against proteasome inhibition.
Methods
Chemicals
Unless specified otherwise, analytical reagents
and reagents of cell culture grade were purchased
from Amersham Biosciences (Uppsala, Sweden). PSI, N-
benzyloxycarbonyl-Ile-Glu (O-t-butyl)-Ala-Leu-al, was
from EMD Biosciences (an affiliate of Merck Chemicals,
Darmstadt, Germany). Cell culture plastics, culture
media and supplying chemicals were from Gibco (Grand
I s l a n d ,N Y ,U S A ) .D N a s eIa n dR N a s eAw e r ef r o m
TaKaRa Biotechnology (Dalian, China). Percoll (density
1.131 g/ml) and proteinase inhibitors [4-(2-aminoethyl)
benzenesulfonyl fluoride, pepstatin A, E-64, bestatin,
leupeptin, and aprotinin] were from Sigma (St. Louis,
USA). Mouse anti-rat alpha-SYN monoclonal antibody
(4D6: sc-65500) and mouse anti-rat histone H1 mono-
clonal antibody (sc-56694) were from Santa Cruz
Biotechnology (California, USA); mouse anti-rat P4HB
monoclonal antibody (MAB2073) was from Chemicon
(Fuji, Japan). Cy3-conjugated goat anti-mouse secondary
antibody (00009-1) was from Proteintech Group
(Chicago, USA).
Cell culture
PC12 cells were purchased from Cell Bank of the Chinese
Academy of Science (Shanghai, China), and their culture
was carried out as described elsewhere [25].
Proteasome inhibition and cell survival
PC12 cells, seeded at a density of 1 × 10
5 cells/ml in
96-well plates and incubated for 24 h, were exposed to
10 μM PSI or equal volume of its vehicle, 0.1% DMSO
(V/V) in culture medium, for 48 h [25]. Then, they were
centrifuged at 1000 rpm (or 93 × g), 4°C for 5 min
[101] and stained with 50 μlo f1 %t r y p a nb l u e( W / V )
for 2 min [102]. After supernatant was removed from
the cell cultures, living cells at a density of at least 100
cells per field were viewed under an upright fluores-
cence microscope with IF550 green interference filter in
the light path. The number of living cells was counted
in nine random fields (three fields per well of a 96-well
plate, three different wells) and expressed as a percen-
tage [103,104]. Chi square test (c
2 test) was used to
determine whether a percent difference was significant
between the cells without and with PSI exposure. Prob-
ability value (P) < 0.05 was accepted as significant. Mea-
surements were repeated at least 3 times.
Formation and isolation of PSI-induced inclusions
Formation of PSI-induced inclusions and their isolation
through cellular fractionation were carried out as
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were subjected to the H&E histological staining to
monitor appearance of the PSI-induced inclusions. Pro-
gress in the isolation of PSI-induced inclusions included
two sequential stages: separation for an abundant frac-
tion of intact PSI-induced inclusions, and purification
for preparation of the target fraction. At the first stage
of isolation, briefly, cells in PSI for 48 h were scraped,
collected and washed in ice-cold Tris-buffered saline
solution (TBS; pH 7.4) and ice-cold 8% sucrose (W/V)
in 0.1 × TBS one after the other. The fraction of the
cells was frozen repeatedly with liquid nitrogen, and
homogenized with a certain amount of lysing buffer
consisting of 1 mM Hepes (pH 7.2), 0.5 mM MgCl2,
0.5% NP-40 (V/V), 0.1% beta mercaptoethanol (V/V),
and 1% proteinase inhibitors (V/V). After repeated sus-
pension and vibration, the lysate was incubated at 37°C
for 30 min until the cells were thoroughly homogenized.
Initial pellets were collected by low speed centrifugation
at 80 × g for 15 min, washed in ice-cold buffer solution
L consisting of 1 mM Hepes, 0.5 mM MgCl2 and protei-
nase inhibitors, and recollected by centrifugation at
836 × g.
At the second stage of isolation, the fraction of initial
pellets was subjected to the H&E histological staining to
monitor presence of the eosinophilic PSI-induced inclu-
sion. In the next isolation, four equal aliquots removed
from the fraction of initial pellets were incubated in 200
U/ml DNase I alone in DNase I buffer plus proteinase
inhibitors at 37°C for 1 h, 6 h, 12 h and 24 h, respec-
tively, whereas another equal aliquot from the fraction
was incubated in the DNase I solution with addition of
250 μg/ml RNase A at 37°C for 24 h. In their respective
incubations, initial pellets were repeatedly suspended
and vibrated vigorously. After incubation, the first four
temporary fractions of resulting pellets and the final one
were collected by centrifugation at 836 × g, washed with
0.32 M sucrose in TBS, and subjected to the H&E histo-
logical staining to monitor presence of the eosinophilic
PSI-induced inclusion.
The final fraction of the resulting pellets was diluted
to 600 μl using 12% Percoll in TBS (V/V) and overlaid
on equal volume of 35% Percoll in TBS. The material
band just below the interface of the sample and 35%
Percoll was removed, collected by centrifugation at
35,000 × g, washed in 250 mM sucrose in 10 mM Tris
(pH 8.0), and recollected by centrifugation at 4000 × g.
This isolated fraction of PSI-induced inclusions was the
preparation of target fraction. The target fraction was
subjected to the a-SYN immunostaining and the H&E
histological staining to monitor presence of the PSI-
induced inclusion, and then subjected to the Western
blotting for histone H1 to monitor contamination of
nuclear protein content.
Assessment of PSI-induced inclusions
Eosinophilic PSI-induced inclusions were examined by
an experienced observer not familiar with the sample
identity. The cells exposed either to the vehicle or to
PSI, the fraction of initial pellets, and the five fractions
of resulting pellets were all subjected to the H&E histo-
logical staining, as previously described [25]. The num-
ber of PSI-induced inclusions was counted in nine
random fields (three fields per section, three different
sections on slide), and expressed as a percentage of
nucleus-free to total PSI-induced inclusions. The c
2 test
was used to determine whether there was significant dif-
ference in the percentage between every two objects of
comparison as follows: between the cells in PSI and the
fraction of initial pellets, between the first one tempor-
ary fraction of resulting pellets and each of the other
three temporary fractions of resulting pellets, and
between each of the four temporary fractions of result-
ing pellets and the final fraction of resulting pellets. P <
0.05 was accepted as significant. Measurements were
repeated at least three times.
The isolated fraction of PSI-induced inclusions,
together with a control (cells in PSI), was first subjected
to the alpha-SYN immunostaining and then the H&E
histological staining. In the application of immunostain-
ing for alpha-SYN, briefly, the isolated fraction of PSI-
induced inclusions was spun on slides and fixed in 4%
paraformaldehyde (W/V). Sections on the slides were
permeabilized with phosphate-buffered saline containing
Triton X-100 (PBS-T; V/V), blocked in 5% bovine
serum albumin (BSA; V/V) in PBS for 1 h, incubated
with primary antibody at 1:50 dilution in PBS at 37°C
for 3 h and incubated with secondary antibody at dilu-
tion 1:100 in PBS-T at 37°C for 3 h, and mounted with
80% glycerol (V/V). The dilutions of primary and sec-
ondary antibodies were according to the reference to
manufacturer’s instructions and the description in litera-
ture [105]. Control sections were examined, as described
above, excluding primary antibody in PBS. Measure-
ments were repeated at least three times.
The isolated fraction of PSI-induced inclusion, together
with two controls (cells in PSI and in the vehicle), was
subjected to the Western blotting for histone H1. Briefly,
the isolated fraction of PSI-induced inclusion was frozen
repeatedly with liquid nitrogen, and dissolved with a cer-
tain amount of lysing solution consisting of 30 mM Tris,
7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl) -
dimethylammonio]-1-propanesulphonate (CHAPS; W/
V), 60 mM dithiothreitol (DTT), and proteinase inhibi-
tors. The mixture was incubated, concussed, and col-
lected by centrifugation at 25,000 × g, 4°C for 30 min.
Approximately 20 μg of protein extracts adjusted to a
total volume of 20 μl was resolved by polyacrylamide gel
electrophoresis in a gel buffer. A 0.5-mm-thick
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ing gel layer was determined by 0.1% sodium dodecyl
sulfate (SDS; W/V), 15% total gel (T; W/V), and 2.6%
cross-linking agent (C; W/W). Protein markers with a
range of 23-132 kD were used to measure molecular
masses of the resolved proteins. After the gel was trans-
ferred to a polyvinylidene difluoride membrane, the
membrane was blocked in 5% BSA in PBS-T at 37°C for
1 h, incubated with primary antibody at 1:100 dilution in
1% BSA in PBS-T at 4°C overnight and incubated with
secondary antibody at 1:500 dilution in 1% BSA in PBS-T
at 37°C for 2 h. The blotted membrane was scanned
using a Typhoon 9400 fluorescent laser scanner (Emis-
sion filter at 580 BP Cy3 mode, wavelength at 532 nm;
Amersham Biosciences) with Typhoon Scanner Control
Version 3.0 (Amersham Biosciences). The digitalized
image of the immunoblot was analyzed with DeCyder
Image QuantTM Version 5.0 (Amersham Biosciences).
Bands of histone H1 in image were densitometrically
quantified using ImageQuant Version 5.0 (Amersham
Biosciences). Dilutions of both primary and secondary
antibodies were according to the reference to manufac-
turer’s instructions and the description in literature
[26,27]. Control blotting membrane was carried out, as
described above, excluding primary antibody in 1% BSA
in PBS-T. Measurements were repeated at least three
times.
Protein extraction, 2-D gel electrophoresis and image
analysis
Protein extraction, 2-D gel electrophoresis and image
analysis were carried out as described elsewhere
[25,106]. Briefly, the isolated fraction of PSI-induced
inclusion, frozen repeatedly with liquid nitrogen, was
dissolved with a lysis buffer consisting of 30 mM Tris,
7 M urea, 2 M thiourea, 4% CHAPS, 60 mM DTT, 2%
pharmalyte (Ph 3.0-10.0; V/V) and proteinase inhibitors.
The mixture was incubated, sonicated, and collected by
centrifugation at 25,000 × g, 4°C for 30 min. A certain
amount of protein extracts prepared from the isolated
fraction of PSI-induced inclusion, together with two
controls prepared from cells in PSI and the vehicle,
were demineralized with 2-D Clean-Up kit, re-dissolved
with a rehydration solution consisting of 8 M urea, 2%
CHAPS (W/V), 0.6% DTT (W/V), and 0.5% immobilized
pH gradients buffer (V/V), and applied to a non-linear
Immobiline™ DryStrip IPG gel strip (pH 3.0-10.0; 24 cm;
Amersham Biosciences). The first dimension electro-
phoresis was run on an Ettan IPGphor II Isoelectric
Focusing Unit (50 μA per strip; Amersham Biosciences).
The strip was then equilibrated in a loading solution
consisting of 50 mM Tris-HCl (pH 8.8), 6 M urea, 2%
SDS, 30% glycerol, 2% DTT and a trace of bromophenol
blue, re-equilibrated in the same loading solution
including 4% (W/V) iodoacetamide but excluding DTT,
and placed onto the top of polyacrylamide gel (24 × 20
cm
2). A 1-mm-thick continuous polyacrylamide gel sys-
tem without stacking gel layer was determined by 0.1%
SDS, 12.5% T, and 2.6% C. The protein markers were
used to mark positions of proteins resolved in gel. The
second dimension electrophoresis was run on an Ettan
DALT six electrophoresis unit (2 W per gel, 600 V, 400
mA; Amersham Biosciences). Coomassie blue-stained
gels were scanned using an Umax CE scanner (Amer-
sham Biosciences) with Image Master Labscan version
3.01b (Amersham Biosciences). The digitalized image of
the gels was analyzed with Image Master 2-D Evolution
version 2003.02 (Amersham Biosciences). Spots in
images were densitometrically quantified and statistically
evaluated by pattern analysis of computer-assisted pit
assessment to detect whether spots appeared reproduci-
bly significant in at least 3 of the 4 gels. These protein
spots of interest were selected for MS analysis. If a spot
was not detected in at least 3 of the 4 gels, it was con-
sidered to be negligible in the present experimental
condition.
In-gel digestion, MS and database search
In-gel digestion, MS and database search were carried
out as described elsewhere [25,107]. Briefly, using an
Ettan Spot Picker robotic workstation (Amersham
Biosciences), the protein spots of interest were automa-
tically selected, excised and placed in 96-well plates at a
gel plug per well. Using an Ettan TA Digester robotic
workstation (Amersham Biosciences), the gel plugs were
twice destained, dehydrated, desiccated and incubated in
10 μlo f1μg/μl modified porcine trypsin at 4°C over-
night, and after which the digested peptide fragments
were extracted twice and the two combined extracts
were desiccated in other 96-well plates. Using an Ettan
Spotter robotic workstation (Amersham Biosciences),
0.3 μl of the digested peptide fragments and an equal
volume of 4 μg/μl a-cyano-4-hydroxy-transcinnamic
acid were deposited on the surface of a sample slide
(Amersham Biosciences). The pre-mix was allowed at
room temperature to facilitate uniform dispersion of the
digested peptide fragments in a large mix.
Signals of MS were recorded in the positive ion reflec-
tion mode on a MALDI-TOF Pro workstation (Amer-
sham Biosciences). The preset threshold values suitable
for acquiring and processing MS were referred to our
previous requirements [25]. Additionally, the most
intensive signals of MS had to be characterized by at
least 3 to 5 strongest peaks. Such an additional criterion
can efficiently distinguish the target protein from the
interference background, since experimental spectra for
protein identification consist of the mass and intensity
pairs, one pair for each peak [108].
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plished using the ProFound search engine against the
latest version of the single NCBInr database (fully inte-
grated and included in the Pro workstation or at http://
prowl.rockefeller.edu/prowl-cgi/profound.exe), and was
further enhanced using Mowse score-based Mascot
search engine against the latest version of the multiple
NCBInr, SwissProt, MSDB databases http://www.
matrixscience.com/search_form_select.html. In the
initial identification, the requirements of evaluation
standard were allowed as follows: sequence coverage of
at least 20%, expectation as much as 0.05, a set of at
least 5 matched peptides, a n dag a po fa tl e a s t3p e p -
tides between the accepted protein candidate and the
first excluded one in the list of protein candidates pro-
vided by the single NCBInr database [25]. For the
enhancement of identification, except that mass toler-
ance at ± 0.2 D as a preset start-up value of searching
parameter for the single database is different from mass
tolerance at ± 0.1 D for the multiple databases, the
others were identical in the two types of protein data-
bases [25]. A protein, if assigned as the identical protein
candidate against the two types of protein databases,
was ultimately determined.
Immunostaining
Cells exposed to PSI for 12, 24, 36 and 48 h, respec-
tively, and a fraction of inclusions isolated from cells in
PSI for 48 h were first subjected to the P4HB immunos-
taining and then the H&E histological staining. The
dilutions of both primary (1:40) and secondary (1:100)
antibodies were carried out according to the reference
to manufacturer’s instructions and the description in lit-
erature [109].
Additional material
Additional file 1: A list of proteins identified from an isolated
fraction of PSI-induced inclusions in PC12 cells by MALDI-TOF MS
PMF. MS data were specifically searched for proteins by proteomic
analysis.
Additional file 2: MS spectra of the unknown proteins of interest.
The eight proteins were incompletely determined by the Profound
search engine using the single NCBInr database alone.
Additional file 3: A list of the identified chaperone proteins with
both putative similarities between protein families and predictable
resources for subcellular localization. A portion of seventeen
chaperone proteins have been found in available literatures to share
some similarity between protein families and to specialize in various
cellular localization resources.
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